Search clinical trials for: Humira (adalimumab)

Total 672 results

Abbott

Withdrawn

Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (ELAN)

Psoriatic Arthritis
Abbott

Completed

Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis (DALI)

Rheumatoid Arthritis

Spain
Abbott

Terminated

Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira (VIVIR)

Rheumatoid Arthritis

Puerto Rico
Hvidovre University Hospital
Abbott

Completed

Humira in Rheumatoid Arthritis - Do Bone Erosions Heal? (HURRAH)

Arthritis | Joint Diseases | Rheumatoid Arthritis

Denmark
Pfizer

Completed

Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)

Healthy

United States, Belgium
Abbott

Completed

A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis (PRIDE)

Psoriasis

Canada
Sandoz
Hexal AG

Completed

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis (ADMYRA)

Rheumatoid Arthritis

United States, United Kingdom, Hungary, Italy, Malaysia, Serbia, Mexico, Spain, Czechia, Poland, Germany, Romania, Russian Federation
Radboud University Medical Center
Erasmus Medical Center

Active, not recruiting

Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients (LADI)

Crohn Disease | Crohn Disease in Remission

Netherlands
Biocad

Completed

Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers

Healthy

Russian Federation
Dr. FRANCISCO J. BLANCO-GARCIA

Completed

A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis

Psoriatic Arthritis

Spain
Shanghai Henlius Biotech

Completed

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Immune System Disorder

China
AbbVie

Completed

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Japan
Wake Forest University

Withdrawn

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Sarcoidosis

United States
Abbott

Withdrawn

A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma

Asthma
Abbott

Completed

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) (RHAPSODY)

Ankylosing Spondylitis

France, Germany, Greece, Italy, Switzerland, Spain, United Kingdom, Belgium, Austria, Netherlands, Norway, Denmark, Finland, Ireland, Sweden
Mylan Inc.
Mylan GmbH

Completed

MYL-1401A Efficacy and Safety Comparability Study to Humira®

Psoriasis | Arthritis, Psoriatic

Bulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
University of Alberta

Completed

Adalimumab for Inflammatory Osteoarthritis

Osteoarthritis

Canada
Abbott

Completed

Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Crohn's Disease

Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Norway, Portugal, Slovakia, Spain, Sweden, Switzerland, United Kingdom
Turgut İlaçları A.Ş.

Completed

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Healthy Participants

Germany
Wake Forest University Health Sciences

Withdrawn

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Pyoderma Gangrenosum

United States
AbbVie (prior sponsor, Abbott)

Completed

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (PIONEER (OLE))

Hidradenitis Suppurativa
University Hospital, Tours

Completed

Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) (AFORA)

Rheumatoid Arthritis

France
The Rheumatological Center of Helsinki
Abbott

Unknown

REstore Working Ability in RheumatoiD Arthritis (REWARD)

Rheumatoid Arthritis

Finland
Rafic Hariri University Hospital
American University of Beirut Medical Center

Unknown

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study (ADA01)

Uveitis | Diabetic Retinopathy | Choroidal Neovascularization

Lebanon
University of North Carolina, Chapel Hill
AbbVie

Completed

Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

Psoriasis

United States
Alvotech Swiss AG

Completed

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Poland, Georgia, Iceland, Russian Federation, Ukraine
AbbVie (prior sponsor, Abbott)

Completed

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Rheumatoid Arthritis

United States, Belgium, Czech Republic, Germany, Puerto Rico, Romania, Slovakia
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER I)

Hidradenitis Suppurativa (HS)
Abbott

Completed

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis (ReAlise)

Rheumatoid Arthritis

Australia, Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, United Kingdom
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira (ADACCESS)

Plaque Type Psoriasis

United States, France, Bulgaria, Slovakia
Abbott

Completed

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Canada
Abbott

Completed

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis (ATLAS)

Ankylosing Spondylitis

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (PIONEER II)

Hidradenitis Suppurativa (HS)
AbbVie

Completed

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease
AbbVie

Completed

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Pyoderma Gangrenosum

Japan
Abbott

Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
AbbVie
Pivotal S.L.; Laboratorio Echevarne

Completed

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA)

Moderate to Severe Crohn's Disease
AbbVie

Completed

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Rheumatoid Arthritis

China
Abbott
Eisai Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Austria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Psoriasis

Psoriasis

Japan
Abbott

Completed

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) (ACCESS)

Crohn's Disease

United States
Abbott

Completed

A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis (ReAct)

Rheumatoid Arthritis
Abbott

Approved for marketing

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab (PROWD)

Rheumatoid Arthritis
AbbVie

Completed

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis (VISUAL III)

Uveitis
AbbVie (prior sponsor, Abbott)

Completed

Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis

Ulcerative Colitis
Peter Higgins
AbbVie

Withdrawn

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) (CADHUM)

Crohn's Disease

United States
Grupo Espanol de Trabajo en Enfermedad de Crohn...
Abbott; TFS Trial Form Support

Terminated

Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (ADACAL)

Crohn's Disease | Mucosal Inflammation

Spain, France, Belgium
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan

3

Subscribe